Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472), announces that its Board of Directors has approved the acquisition of US-based Pyros Pharmaceuticals, Inc. (“Pyros”), a specialty pharmaceutical company developing treatments for rare diseases. Founded in 2017 by Michael Smith and Edwin Urrutia, Pyros recently launched VIGAFYDE™ (vigabatrin) oral solution, which is indicated as monotherapy for the treatment of infantile spasms (IS) in pediatric patients 1 month to 2 years, where the potential benefits outweigh the potential risk of vision loss. Infantile spasms, a rare but severe form of epilepsy, pose significant challenges for patients and their families.
Read the full article: Bora Pharmaceuticals to Expand Rare Disease Portfolio with Acquisition of US-Based Pyros Pharmaceuticals //
Source: https://www.prnewswire.com/news-releases/bora-pharmaceuticals-to-expand-rare-disease-portfolio-with-acquisition-of-us-based-pyros-pharmaceuticals-302287398.html